Kiniksa Pharmaceuticals International (KNSA) Equity Average (2018 - 2026)

Kiniksa Pharmaceuticals International has reported Equity Average for 9 years, with the latest figure at $586.6 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 30.96% year-over-year to $586.6 million; the trailing twelve-month figure through Mar 2026 stood at $586.6 million (up 30.96% YoY), and the FY2025 full-year result was $503.0 million, up 14.68% from the prior year.
• Equity Average for Q1 2026 stood at $586.6 million, up from $551.5 million in the prior quarter.
• The five-year high for Equity Average was $586.6 million in Q1 2026, with the low at $159.9 million in Q2 2022.
• Historically, Equity Average has averaged $408.2 million across 5 years, with a median of $433.5 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average plunged 39.71% — and 2023, when it surged 150.75%.
• Kiniksa Pharmaceuticals International's Equity Average stood at $390.1 million in 2022, then gained by 8.18% to $422.0 million in 2023, then rose by 3.73% to $437.7 million in 2024, then gained by 25.99% to $551.5 million in 2025, then grew by 6.37% to $586.6 million in 2026.
• The last three Equity Average figures came in at $586.6 million (Q1 2026), $551.5 million (Q4 2025), and $515.2 million (Q3 2025), per Business Quant data.